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Abstract 
Introduction: Critical illness from SARS-CoV-2 infection (COVID-19) is associated with a high burden of pulmonary 
embolism (PE) and thromboembolic events despite standard thromboprophylaxis. Available guidance is discordant, 
ranging from standard care to the use of therapeutic anticoagulation for enhanced thromboprophylaxis (ET). Local ET 
protocols have been empirically determined and are generally intermediate between standard prophylaxis and full 
anticoagulation. Concerns have been raised in regard to the potential risk of haemorrhage associated with therapeu-
tic anticoagulation. This report describes the prevalence and safety of ET strategies in European Intensive Care Unit 
(ICUs) and their association with outcomes during the first wave of the COVID pandemic, with particular focus on 
haemorrhagic complications and ICU mortality.
Methods: Retrospective, observational, multi-centre study including adult critically ill COVID-19 patients. 
Anonymised data included demographics, clinical characteristics, thromboprophylaxis and/or anticoagulation treat-
ment. Critical haemorrhage was defined as intracranial haemorrhage or bleeding requiring red blood cells transfusion. 
Survival was collected at ICU discharge. A multivariable mixed effects generalised linear model analysis matched for 
the propensity for receiving ET was constructed for both ICU mortality and critical haemorrhage.
Results: A total of 852 (79% male, age 66 [37–85] years) patients were included from 28 ICUs. Median body mass 
index and ICU length of stay were 27.7 (25.1–30.7) Kg/m2 and 13 (7–22) days, respectively. Thromboembolic events 
were reported in 146 patients (17.1%), of those 78 (9.2%) were PE. ICU mortality occurred in 335/852 (39.3%) patients. 
ET was used in 274 (32.1%) patients, and it was independently associated with significant reduction in ICU mortality 
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Background
A growing body of observational clinical evidence indi-
cates that coronavirus disease (COVID‐19) is associ-
ated with a high incidence of thrombotic complications 
[1–4]. Despite standard anticoagulant thromboprophy-
laxis, the burden of thrombotic complications—primarily 
pulmonary embolism (PE)—remains high in COVID-19 
patients, in particular among those requiring intensive 
care unit (ICU) admission. Recent studies on COVID-
19 patients have reported an incidence of thromboem-
bolic events ranging from 27 to 57% [5] despite standard 
thromboprophylaxis, and a recent review of studies 
including a total of 1765 hospitalised patients (mixed 
cohort of patients admitted to the ICU or the ward) 
reported the occurrence of venous thromboembolism 
(VTE) in approximately 20% of patients, with cumulative 
prevalence up to 49% during hospitalisation [6].
Although observational clinical data suggest that 
the use of either prophylactic to increased doses of 
low molecular weight heparins (LMWH) in high-risk 
patients may be associated with better prognosis, the 
optimal thromboprophylaxis strategy in the critically ill 
COVID-19 patient population remains uncertain [7]. In 
the absence of evidence from randomised controlled tri-
als, published guidance based on observational data and 
expert opinion has been heterogeneous and sometimes 
contradictory, ranging from standard treatment to a vari-
ety of ET protocols with varying levels of anticoagulation 
from enoxaparin 40  mg BD to full therapeutic antico-
agulation with unfractionated heparin [8–11]. Recently, 
three randomised clinical trials aimed to test the effects 
of full doses of anticoagulants in COVID-19 patients 
have paused enrolment for futility, questioning the bene-
fit of giving full dose anticoagulants routinely in critically 
ill COVID-19 patients and raising concerns regarding the 
safety of widespread ET protocols [12].
The purpose of this study was therefore to describe 
the prevalence of ET strategies in European Intensive 
Care Unit (ICUs) and to assess their association with 
ICU mortality and safety in a large cohort of critically ill 
COVID-19 patients admitted to European ICUs during 
the first wave of the pandemic.
Methods
Study population and data collection
This is an observational, retrospective multi-centre study, 
including 28 European ICUs. The study was conducted 
according to the Strengthening the Reporting Obser-
vational Studies in Epidemiology (STROBE) Statement 
guidelines (Supplementary material Section S1). Each 
participating centre obtained the approval for data col-
lection from its local Ethical Committee. The need for 
written informed consent was waived for retrospectively 
collected data. In each centre, consecutive adult patients 
(age ≥ 18) with a confirmed COVID-19 diagnosis requir-
ing ICU admission in the period between 26 February 
and 30 May 2020 were included. Participating units were 
provided with a study protocol and case report form 
(CRF). A detailed list of all variables collected in the CRF 
is provided in supplementary material (section S6). For 
each centre a trained physician collected, curated and 
submitted anonymised data for analysis to the coordi-
nating centre (Cambridge, UK). Analysis was performed 
by AE, CR and AL. Data included patient demographics 
[age; gender; weight; body mass index, BMI], past medi-
cal history [hypertension, diabetes, renal failure, cardiac 
failure, renal failure], date of ICU admission and dis-
charge, ICU mortality, mode of death [respiratory failure, 
multiorgan failure, major haemorrhage, cardiocircula-
tory collapse], renal failure [acute kidney injury (AKI), 
need for renal replacement therapy (RRT)], thromboem-
bolic events [i.e. pulmonary embolism (PE), deep venous 
thrombosis (DVT), arterial embolism, line clotting] and 
haemorrhagic events [critical (i.e. intracranial bleed or 
requiring transfusion), non-critical (i.e. others)]. Data 
regarding any antiplatelet therapy, thromboprophylaxis 
and therapeutic anticoagulation at ICU admission were 
also obtained. Participating centres were requested to 
indicate whether patients were treated with standard 
prophylaxis (group ‘standard prophylaxis’) or COVID-19 
(log odds = 0.64 [95% CIs 0.18–1.1; p = 0.0069]) but not an increased risk of critical haemorrhage (log odds = 0.187 
[95%CI − 0.591 to − 0.964; p = 0.64]).
Conclusions: In a cohort of critically ill patients with a high prevalence of thromboembolic events, ET was associ-
ated with reduced ICU mortality without an increased burden of haemorrhagic complications. This study suggests 
ET strategies are safe and associated with favourable outcomes. Whilst full anticoagulation has been questioned for 
prophylaxis in these patients, our results suggest that there may nevertheless be a role for enhanced / intermediate 
levels of prophylaxis. Clinical trials investigating causal relationship between intermediate thromboprophylaxis and 
clinical outcomes are urgently needed.
Keywords: COVID-19, Intensive care medicine, Thrombosis, Heparin, Prophylaxis, Anticoagulation
Page 3 of 10Lavinio et al. Crit Care          (2021) 25:155  
specific ‘enhanced thromboprophylaxis’ according to 
local protocols (group ‘ET’) and which molecule was 
used (presented as two subgroups ‘ET enoxaparin’ and 
‘ET other’). Authors were asked to describe local proto-
cols, including whether anti-Xa monitoring was routinely 
used for titration. Patients already on therapeutic antico-
agulation at the time of ICU admission for established or 
suspected thromboembolic events were included in the 
group ‘therapeutic anticoagulation for indications other 
than prophylaxis’.
Statistical analysis
Statistical analysis was performed in R 3.6.3 [13]. The 
data collection and curation process are described in the 
DAQCORD statement given in supplementary materi-
als S2 [14]. Kaplan–Meier ICU survival curve plot for the 
various anticoagulation groups was performed (Fig.  1). 
Modelling was undertaken using the lme4 v1.1-25 [15], 
MICE v3.11.0 [16] and MatchIt v4.0.0 [17] packages. Sta-
tistical significance was taken as p < 0.05, and corrections 
for multiple comparisons were not made. Multiple impu-
tations using a predictive mean matching method on all 
variables were used to generate 50 complete datasets. 
Outcomes were included in the imputation but subjects 
with missing outcomes excluded from the final matching 
for statistical efficiency. For each imputed dataset, pro-
pensity scores for receiving ET for thromboprophylaxis 
were estimated using a mixed effects model including 
age, BMI, medical history (presence/absence of hyper-
tension, diabetes or renal disease), D-dimers on admis-
sion, C-reactive protein, fibrinogen, platelet count, white 
blood cell count, intubation status and antiplatelet agent 
use, as fixed effects and site code as a random effect. Pro-
pensity matched datasets were then constructed using 
a nearest neighbour approach before fitting additional 
mixed effects models for ICU survival and for, with the 
same covariates and random effects on each of these 
matched datasets. The final results were then pooled.
Results
Study population
Data completeness was good and is summarised in sup-
plementary materials (Additional file  1: section S3). 
Anonymised data for 852 patients were provided by 28 
collaborating European sites. Patient characteristics are 
summarised in Table  1. Six hundred and seventy-seven 
(79.5%) were male, and median age was 66 [37–85] 
years. Hypertension and obesity were the most com-
mon comorbidities, occurring in the 52.3% and 27.6% 
of patients, respectively. Median body mass index (BMI) 
was 27.7 [25.1–30.7] Kg/m2.
Median distribution of BMI in the enhanced prophy-
laxis group did not differ from those in the rest of the 
patients (p = 1) (Additional file 1: section S4, Figure S2). 
Distribution of ICU admission fibrinogen, platelet count, 
prothrombin time, D-dimer C-reactive protein and white 
Fig. 1 Kaplan–Meier plot stratified by anticoagulation status: Standard prophylaxis, enhanced prophylaxis with LMWH (light purple), enhanced 
prophylaxis with other agent (darker purple), anticoagulated for non-prophylaxis indication. In this unmatched analysis, a trend towards improved 
survival with enhanced prophylaxis (purple curves) is apparent
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Table 1 Demographics, blood tests results at intensive care unit (ICU) admission and during ICU stay, outcomes and complications of 
the overall population and according to different subgroups
IQR, interquartile range; BMI, body mass index; WBC, white blood cells;  PaO2,partial pressure of oxygen; AKI, acute kidney injury; RRT, renal replacement therapy; DVT, 










(N = 38, 4.5%)
Standard prophylaxis
(N = 435, 51%)
Anticoagulation for indication 
other than prophylaxis [i.e. PE / 
DVT on admission]
(N = 143, 16.8%)
Sex, male, n (%) 677 (79.5) 187 (79.2) 31 (81.6) 340 (78.2) 119 (83.2)
Age, years 66 (37–85) 66 (37–85) 65.5 (37–86) 66 (16–87) 67 (27–85)
Comorbidities, n (%)
Hypertension 446 (52.3) 127 (53.8) 16 (42.1) 217 (49.9) 57 (39.9)
Diabetes mellitus 143 (16.8) 37 (15.7) 1 (2.6) 79 (18.2) 26 (18.2)
Renal disease 44 (5.2) 14 (5.9) 0 (0.0) 29 (6.7) 1 (0.7)
Cardiac dysfunction 86 (10.1) 26 (11) 1 (2.6) 41 (9.4) 18 (12.6)
Liver disease 16 (1.9) 2 (0.8) 2 (5.2) 10 (2.3) 2 (1.4)
Obesity (BMI > 30 kg/m2) 235 (27.6) 72 (30.5) 10 (26.3) 111 (25.5) 42 (29.4)
Bloods at ICU admission, median (IQR)
WBC, cells ×  109/L 9.0 (1–89) 10.6 (1–46) 9.4 (3–18) 9.0 (2–89) 9.1 (3–45)
D-dimer, ng/mL 1340 (150–136,076) 1610 (93–105,990) 2291 (180–76,400) 1207 (150–129,064) 1484 (85–136,076)
Platelets,  cells3/µL 223 (31–734) 218 (255–654) 219 (133–517) 218 (200–734) 234 (70–814)
Fibrinogen, mg/dL 637 (77–1323) 613 (100–1276) 649 (163–999) 635 (40–1196) 626.5 (77–1323)
C-reactive protein, mg/L 102.3 (1–559) 146 (0–559) 162 (3–387) 136.5 (0–393) 138.5 (1–255)
Troponin-I, ng/mL 0.02 (0–6) 0.02 (0–2) 0.03 (0–0) 0.02 (0–21) 0.02 (0–3)
Creatinine, mg/dL 0.93 (0–7) 0.82 (0–7) 1 (1–3) 0.95 (0–7) 0.9 (0–8)
PaO2, mmHg 80 (25–440) 76.5 (27–316) 67.5 (34–189) 85 (25–440) 83 (39–489)
Bloods during ICU stay, median (IQR)
WBC, cells ×  109/L
 Lowest 6.1 (0–44) 6.0 (1–24) 6.3 (2–18) 6.1 (1–31) 5.9 (1–44)
 Highest 17.5 (2–132) 17.8 (2–132) 15.3 (2–31) 16.8 (3–68) 19.6 (5–80)
D-dimer, ng/mL
 Highest 4395 (176–222,032) 4706.5 (635–222,032) 6320 (703–798,94) 3637.5 (201–57,588) 5273.5 (201–57,588)
Platelets,  cells3/µL
 Lowest 169 (110–510) 174 (30–315) 189 (91–476) 173 (18–510) 146 (11–476)
 Highest 380 (700–981) 397 (175–981) 417 (154–645) 379 (118–953) 366 (70–645)
Troponin-I, ng/mL
 Highest 0.04 (0–10) 0.03 (0–2) 0.03 (0–0) 0.03 (0–10) 0.05 (0–5)
Creatinine, mg/dL
 Highest 1.4 (0.4–14) 1.3 (0–12) 1.2 (1–6) 1.4 (0–9) 1.6 (1–14)
PaO2, mmHg
 Lowest 61 (26–150) 61 (30–107) 60.9 (34–88) 61 (26–150) 62 (33–130)
Thromboembolic complications* n (%)
Arterial embolism 8 (0.9) 6 (2.5) 0 (0.0) 2 (0.5) 0 (0)
DVT 28 (3.2) 11 (4.6) 0 (0.0) 17 (3.9) 0 (0)
Line clotted 21 (2.4) 5 (2.1) 1 (2.6) 15 (3.4) 0 (0)
Pulmonary embolism 57 (6.6) 21 (8.8) 4 (10.5) 32 (7.4) 0 (0)
No/NA 738 (86.6) 193 (82.0) 33 (86.9) 369 (84.8) 0 (0)
Haemorrhagic complications n (%)
Critical haemorrhage 47 (5.5) 12 (5.0) 0 (0.0) 27 (6.2) 8 (5.6)
Non-critical haemorrhage 58 (6.8) 16 (6.9) 2 (5.3) 28 (6.4) 12 (8.4)
No/NA 747 (87.7) 208 (88.1) 36 (94.7) 380 (87.4) 123 (86.0)
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blood cell count in the enhanced prophylaxis group com-
pared to the rest of the patients showed no difference in 
median values (Wilcoxon rank sum all p = 1) (Additional 
file  1: section S4, Figure S3,4). Details on ICU compli-
cations, bloods and therapy according to the different 
groups are presented in Table 1.
Median length of ICU stay was 13 [7–22] days. ICU 
survival status was available for 816 patients: 337 of those 
died (41.3%). In non-survivors, the reported mode of 
death was multiorgan failure 172 (51%), cardiocirculatory 
collapse 87 (25.8%), respiratory failure 73 (21.7%) and 
massive haemorrhage in 3 (0.9%). Of the three deceased 
patients for whom the reported mode of death was mas-
sive haemorrhage, one patient was being treated with ET 
and 2 patients were on standard thromboprophylaxis 
regimens.
Thromboembolic events and anticoagulation regimens
A total of 274 (32.2%) patients received enhanced throm-
boprophylaxis (ET) according to local protocols. The 
majority 236 (27.7%) received ET with enoxaparin (group 
‘ET enoxaparin’) at doses reported ranging from 100 to 
200  IU/Kg/day in two divided doses (i.e. equivalent to 
approximately 40–80  mg twice daily for an 70–90  kg 
adult), with correction for renal failure and bleeding 
abnormalities during the course of ICU stay according to 
local practice.
Only one centre (Bruxelles) reported using anti-Xa 
activity with a target of (0.3–0.5) systematically for dose 
titration. Thirty-eight (4.5%) patients (group ‘ET other’) 
received ET with UFH (38) titrated to heparin ratio of 
1.5–2.5, or fondaparinux (one patient).
Four hundred and thirty-five (51.1%) received throm-
boprophylaxis as per standard protocols (group ‘stand-
ard prophylaxis’). These include 19 (2.2%) patients with 
contraindications to anticoagulation at the time of ICU 
admission who received no heparin. Indications for anti-
coagulation for indication other than prophylaxis (143 
cases, 16.8%) were arterial embolism (1 case, 0.7%), deep 
venous thrombosis (3 cases, 2.1%), line clotted (7 cases, 
4.9%) and pulmonary embolism (21 cases, 14.7%).
Thromboembolic events after ICU admission were 
reported in 114 patients (13.3%), including 57 (6.6%) 
cases of pulmonary embolism. A crude comparison 
between ET and standard prophylaxis (after excluding for 
patients with indications for therapeutic anticoagulation 
other than prophylaxis at time of ICU admission) does 
not reveal a statistical difference in reported thromboem-
bolic events (p = 0.4).
Predictors of outcome and critical haemorrhage
Figure 1 shows a Kaplan–Meier ICU survival curve plot 
for the various anticoagulation groups; a trend towards 
improved survival with enhanced prophylaxis is appar-
ent. The results of the propensity score analysis for ICU 
mortality are summarised in Table  2. A control match 
was found for each of the patients treated with ET. The 
use of ET was independently associated with signifi-
cant reduction in ICU mortality (log odds = 0.64 [95% 
CIs 0.18–1.1; p = 0.0069]) but not an increased risk of 
Table 2 Mixed effects, generalised linear model for ICU survival matched for propensity for use of ‘enhanced’ prophylaxis. Effect sizes 
are unscaled log odds (positive indicates survival benefit)
BMI, body mass index; ICU, intensive care unit; P/F partial pressure of oxygen/inspired fraction of oxygen; CRP, C-reactive protein; WBC, white blood cells
Term Effect size (log odds) p-value 95% CI
(Intercept) 0.38 0.37 − 0.452 1.21
Use of ‘enhanced’ (therapeutic) prophylaxis 0.64 0.0069 0.176 1.1
Age (years) − 12.1  < 0.0001 − 15.6 − 8.69
BMI − 1.34 0.02 − 2.46 − 0.211
History of hypertension − 0.0204 0.94 − 0.53 0.489
History of diabetes − 0.07 0.83 − 0.70 0.563
History of renal disease − 0.951 0.1 − 2.1 0.198
Intubated 2.28 0.00026 1.1 3.5
D-dimer at ICU_admission − 3390 0.38 − 11,000 4180
P/F ratio at ICU admission 18.4 0.13 − 5.24 42
CRP at ICU admission − 19.8 0.26 − 54.3 14.7
Fibrinogen_at ICU_admission − 5.14 0.9 − 89.8 79.5
Platelet count at_ICU_admission 61.5 0.0004 27.7 95.4
WBC at ICU admission − 1.73 0.052 − 3.46 0.0119
Antiplatelet agent use 0.44 0.2 − 0.238 1.12
Page 6 of 10Lavinio et al. Crit Care          (2021) 25:155 
critical haemorrhage (log odds = 0.187 [95%CI − 0.591 to 
− 0.964; p = 0.64]). Older age and high BMI were found 
to be associated with a higher log odds of ICU mortal-
ity (log odds = −12.1 [95% CI − 15.6 to − 8.69; p < 0.0001] 
and −1.34 [95% CI − 2.46 to − 0.211; p = 0.02], respec-
tively). Increased ICU admission platelet count was 
associated with increased log odds of ICU mortality [log 
odds = 61.5 [95% CI 27.7–95.4; p = 0.0004]) as was the 
use of mechanical ventilation [log odds = 2.28 [95% CI 
1.1–3.5; p = 0.00026]. There were no other statistically 
significant predictors of ICU mortality in the multivariate 
model.
Table  3 shows the results of the propensity matched 
analysis for critical haemorrhage. There were no statisti-
cally significant predictors of critical haemorrhage in our 
dataset. Most importantly, ET was not significantly asso-
ciated with an increased risk of critical haemorrhage (log 
odds = 0.187 [95%CI − 0.591 to − 0.964; p = 0.64]).
A sensitivity analysis was performed, repeating both 
propensity models but excluding all patients who 
received full anticoagulation for non-prophylaxis indi-
cations as these might ‘enrich’ the standard group with 
patients with higher risk of mortality due to significant 
thromboembolic disease, biasing the results against 
standard treatment. However, the results were qualita-
tively the same and revealed identical statistically sig-
nificant associations (see Additional file  1: section S5) 
suggesting that our analysis is robust.
Discussion
We report on the wide adoption of empirically ‘enhanced’ 
thromboprophylaxis strategies for critically ill COVID-
19 patients during the first wave of the pandemic. These 
enhanced strategies varied among European centres. The 
most common strategy consisted in increasing LMWH 
prophylaxis to an intermediate range between stand-
ard prophylaxis and full therapeutic anticoagulation. A 
minority of centres opted for full therapeutic anticoagu-
lation with unfractionated heparin.
The main finding of this study is that the introduction 
of ‘enhanced thromboprophylaxis’ strategies was not 
associated with an increased incidence of haemorrhagic 
events and it was associated with increased ICU survival 
in propensity matched analysis.
These findings are of particular relevance in view of 
the recent suspension on the grounds of futility for three 
clinical trials investigating the effects of full doses of anti-
coagulants in critically ill COVID-19 patients [12].
The association of intermediate ‘enhanced thrombo-
prophylaxis’ strategies with the improved survival in the 
absence of increased haemorrhagic complications sug-
gests that standard approaches may safely be augmented. 
Whilst caution needs to be employed given the non-ran-
dom allocation and variances in practice and we do not 
claim statistical significance, the survival curve of Fig. 1 
is consistent with the improved survival with ET found in 
the propensity matched model.
Table 3 Mixed effects, generalised linear model for occurrence of ‘critical haemorrhage’ (intracranial haemorrhage or haemorrhage 
requiring transfusion matched for propensity for use of ‘enhanced’ prophylaxis
Effect sizes are unscaled log odds (positive indicates associate with increased risk of critical haemorrhage)
BMI, body mass index; ICU, intensive care unit; P/F partial pressure of oxygen/inspired fraction of oxygen; CRP, C-reactive protein; WBC, white blood cells
Effect size (log odds) p value 95% CI
(Intercept) − 3.31  < 0.0001 − 4.41 − 2.21
Use of ‘enhanced’ (therapeutic) prophylaxis 0.187 0.64 − 0.591 0.964
Age (years) − 3.57 0.1 − 7.85 0.713
BMI − 0.83 0.41 − 2.79 1.13
History of hypertension − 0.0719 0.86 − 0.879 0.736
History of diabetes − 0.341 0.55 − 1.47 0.792
History of renal disease − 0.374 0.73 − 2.52 1.77
Intubated − 0.757 0.38 − 2.44 0.931
D-dimer at ICU_admission − 7960 0.33 − 24,000 8070
P/F ratio at ICU admission 8.38 0.62 − 24.6 41.3
CRP at ICU admission 27.7 0.32 − 27 82.4
Fibrinogen at ICU_admission − 89.9 0.14 − 210 30.2
Platelet count at_ICU_admission 2.71 0.91 − 44.6 50
WBC at ICU admission 2.11 0.039 0.11 4.12
Antiplatelet agent use 0.666 0.2 − 0.358 1.69
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Dysregulated coagulation, systemic prothrombotic 
state and local micro-thrombosis associated with acute 
endothelial inflammation, hypoxia, apoptosis and platelet 
activation are the main pathophysiological mechanisms 
underlying COVID-19-related coagulopathy [1–4].
There is fairly convincing evidence that in situ pulmo-
nary artery microthrombi may partly represent the end-
point of pulmonary inflammation [6, 19].
Based on such aetiological considerations, it would 
seem reasonable to assume that therapeutic interven-
tions should primarily target the early stages of the pro-
cess (i.e. inflammation modulation and inhibition of 
platelet activation) rather than the coagulation cascade 
(thus discounting the potential benefits of heparin-based 
treatments) [20]. Moreover, if microvascular coagula-
tion occurs as a manifestation of end-stage lung inflam-
mation, alveolar damage and hypoxia (i.e. pulmonary 
thrombosis seen as a tombstone rather than a risk fac-
tor for cardiocirculatory collapse, respiratory failure and 
fatal outcome), then anticoagulation or thrombolysis 
would incur the risk of precipitating pulmonary haemor-
rhage without proving any benefit [20].
Whilst it is not disputed that immunomodulation and 
inhibition of platelet activation are certainly key targets for 
the care of critically ill COVID-19 patients [21] (dexametha-
sone is the only drug clearly proven to reduce mortality at 
the time of writing [20]), our results support the use of ET 
strategies. Although the mechanisms of heparin resistance 
in critically ill COVID-19 patients remain to be fully elu-
cidated, the phenomenon has been clearly described and 
could be at least partially attributed to high factor VIII and 
fibrinogen and low antithrombin levels typically seen in 
these patients [23]. Heparin resistance with unfractionated 
heparin or sub-optimal anti-Xa peak with low molecular 
weight heparin was confirmed to be a common occurrence. 
It was furthermore confirmed that in  vitro spiking of 
COVID-19 samples from patients in intensive care unit with 
low molecular weight heparin failed to recover the anti-Xa 
level as would have been predicted [24]. In conjunction with 
the evidence of high rate of thromboembolic events despite 
standard thromboprophylaxis, the evidence of heparin 
resistance supports the implementation of increased pro-
phylactic dosing in critically ill COVID-19 patients [21].
Furthermore, preliminary studies reported a signifi-
cant reduction in thromboembolic events for critically ill 
COVID-19 patients treated with empirical ET strategies 
when compared to standard prophylaxis (N = 26, 56% 
vs 100%, p = 0.03) [22]. These findings replicate earlier 
experience in patients developing ARDS secondary to 
influenza A [H1N1], where empirical ‘therapeutic’ hepa-
rin prophylaxis was associated with a 33-fold reduction 
in thromboembolic events, crucially in the absence of 
increased haemorrhagic complications [23].
Massive pulmonary embolism may be a potentially 
reversible cause of death and therefore a potential ther-
apeutic target in critically ill COVID-19 patients. A 
case series of post-mortem autopsies found that venous 
thromboembolism was present in 7 of 12 (58%) patients 
with COVID-19. The study concluded that pulmonary 
embolism had been the direct cause of death in a third of 
cases [15]. This is consistent with our findings of a high 
prevalence of pulmonary embolism and sudden cardi-
ocirculatory collapse and respiratory failure as the most 
prevalent modes of death. Whether this process can be 
prevented or reversed remains to be proven, but in a 
series of three patients with severe COVID-19 respiratory 
failure who were treated with tissue plasminogen activa-
tor a temporally related improvement in respiratory sta-
tus was reported in all cases (with one of them being a 
durable response) suggesting a potential reversibility of 
the process [24].
Risk of haemorrhage
A French single centre study on 92 critically ill COVID-
19 patients reported a 40% prevalence of thrombo-
embolic events (TE) and a 21% rate of ‘significant’ 
thromboembolic events, with most of such events occur-
ring in patients being treated with full dose anticoagu-
lation. The authors concluded: “as half of these patients 
were treated with full-dose pre-emptive anticoagulation 
without a confirmed TE, we must be cautious about our 
thromboprophylaxis strategy with daily reassessment of 
its indication” [25]. Whilst we echo the call for caution, 
the findings of our study seem to indicate that the use of 
ET is not associated with an increased chance of death or 
critical haemorrhagic events.
Practical considerations
Given the high burden of thromboembolic complications 
associated with standard prophylaxis and the absence 
of major haemorrhage related mortality, the imple-
mentation of ‘enhanced’ thromboprophylaxis strategies 
seems justified. Whilst the ideal dosing and stratification 
remains to be determined by randomised clinical tri-
als, the implementation of twice daily standard LMWH 
prophylaxis appears to be reasonable and has the advan-
tage of limiting staff exposure when compared to con-
tinuous UFH infusion and aPTT monitoring. In view of 
the prevalence of renal impairment in this patient pop-
ulation, careful dose adjusting and anti-Xa and aPTT-
ratio monitoring is strongly recommended. Given the 
high prevalence of thromboembolic events even in the 
absence of risk factors [26] and in consideration of lim-
ited validation for risk stratification tools, the authors 
support a standard ‘universal’ approach to ‘enhanced 
thromboprophylaxis’ for critically ill COVID-19 patients.
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Limitations of the study
Our study also has several important limitations. Firstly, 
being a retrospective observational dataset, no definite 
conclusions can be taken in regard to what the ideal 
thromboprophylaxis strategy for critically ill COVID-
19 patients should be as it is impossible to be sure that 
the propensity score captures the true decision making 
in instituting ET in an observational dataset. Secondly, 
as this is an observational and not interventional study, 
each centre relied on its own screening methods for the 
detection of thromboembolic complications, without a 
systematic screening of patients for haemorrhagic and 
thrombotic events. Also, we limited our observations 
and anticoagulant therapy at admission and in the early 
phases of ICU admission, thus reducing the potential 
effect of long-term anticoagulant strategies. Moreover, 
the multicentric nature of the study could potentially 
increase variance and data integration difficulties among 
different centres, which is simply not possible to cor-
rect by means of post hoc analysis. Whilst clearly not as 
robust in demonstrating causality as a well conducted 
randomised controlled trial, our propensity score method 
attempts to exploit ‘natural’ variations in practice within 
and between sites to remove bias from the ET cohort.
Conclusions
Enhanced thromboprophylaxis strategies have been 
widely and empirically implemented across European 
ICUs during the first wave of the pandemic. Thrombo-
embolic events remain highly prevalent. Death associated 
with massive haemorrhage is extremely rare, and it does 
not appear to be associated with ‘enhanced thrombo-
prophylaxis’ strategies, which in this series consisted in 
increasing low molecular weight heparin within an inter-
mediate range between standard prophylactic and full 
therapeutic dose. Within the limitations of its methodol-
ogy, this study supports the continued use of enhanced 
intermediate levels of thromboprophylaxis for critically 
ill COVID-19 patients. Further well designed randomised 
controlled trials are urgently needed to explore the causal 
relationship between the dose of anticoagulation received 
and patients’ outcome in critically ill COVID-19 patients.
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